Prof. Dr. Peter Adolfsson brings you up to date on connected pens, application of CGM metrics, and separated or combined use of the information in non-CSII insulin therapy.
Dear colleagues, welcome to this EASD e-Learning module on connected pens, application of CGM metrics, and separated or combined use of the information in non-CSII insulin therapy. My name is Peter Adolfsson and I’m a senior physician at Högsbo Hospital in Gothenborg in Sweden. In recent years, advancements in diabetes management technology have led to the development of continuous glucose monitoring, which we commonly refer to as CGM, and also connected insulin caps and pens, as well as smart insulin pen systems. For us clinicians, these innovations offer new opportunities for optimising insulin therapy and improving glycaemic control in persons with diabetes who are not using continuous subcutaneous insulin infusion therapy, also called CSII. In this module, we will explore the benefits of using CGM-based metrics in non-CSII, the existing trial evidence related to the use of connected caps or pens and smart MDI systems in people living with diabetes, and the strategies for using smart MDI systems to optimise glycaemic control, including associated challenges. So let’s get started.Video transcript
By the end of this module, you will be able to:
✓ Explain the advantages of using CGM-based metrics in non-CSII insulin therapy.
✓ Specify and explain the strategies used by Smart MDI systems to optimise glycaemic control.
✓ Interpret the existing trial evidence related to the use of connected caps or pens and Smart MDI systems in people living with diabetes
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.